Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Spcm SA has 1 pending office action in the Biotechnology & Pharmaceuticals technology area. This action is assigned to 1 distinct examiner and 1 distinct art unit. This 1 to 1 ratio across the action, examiner, and art unit reflects a specific prosecution focus. By operating within 1 art unit, the company maintains a narrow procedural footprint at the patent office. This structure allows the legal team to focus their resources on the requirements of a specific technical group within the Biotechnology & Pharmaceuticals field.
SINGH, SATYENDRA K is the busiest examiner, with 1 pending office action. This 1 action is the only pending office action for the company. With 1 examiner managing the 1 active action, the company's current prosecution is entirely centralized. For the practitioner, understanding the specific preferences of SINGH, SATYENDRA K is the primary factor in the current prosecution strategy. The outcome of the 1 pending office action will be determined by the review and feedback provided by this identified examiner.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| SINGH, SATYENDRA K | 1 | 61.5% | +67.9% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18565838 | BIOLOGICAL METHOD FOR OBTAINING MONOMERS COMPRISING AN ETHYLENIC UNSATURATION BY BIOCONVERSION OF A BIO-SOURCED COMPOUND COMPRISING AT LEAST ONE NITRILE FUNCTION | SINGH, SATYENDRA K | — |
| Art Unit | Apps |
|---|---|
| 1657 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18565838 | BIOLOGICAL METHOD FOR OBTAINING MONOMERS COMPRISING AN ETHYLENIC UNSATURATION BY BIOCONVERSION OF A BIO-SOURCED COMPOUND COMPRISING AT LEAST ONE NITRILE FUNCTION | SINGH, SATYENDRA K | 1657 | §103 | Final Rejection | — | Pending | Nov 30, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialSpcm SA has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Satyendra K Singh has the most, with 1 of Spcm SA's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
